Pricing Log in Create free account
Friday 6 November 2026 Export PDEX’s income statement to Excel — free account

Pro-Dex, Inc.

PDEX Healthcare Medical Instruments & Supplies

Pro-Dex, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $77.5 million, up 16.5% from fiscal 2025.

Revenue
+11.0%
EPS
−33.6%
Free cash flow
+177.8%
Total debt
+42.2%

Quarter to September 2026, against a year earlier

61.57 1.87 −2.95%
Market cap
$195.8M
P/E
16.4×
Fwd P/E
18.8×
Dividend yield
—
F-score
6/9
Altman Z
7.38
Beneish M
−1.11
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.03
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 1 — 1 — — — 3 — —
Insider Ownership 36.37%

Capital & Financial Ratios $m

Size
Market Cap 195.84
Revenue ttm 79.58
Net income ttm 12.03
Free cash flow ttm 10.69
Net debt Q (0.72)
Valuation
P/E 16.42
Forward P/E 18.80
Price / sales 2.48
Forward P/S Powerpack
Price / FCF 18.52
Price / book 4.00
Financial health
Current ratio Q 4.19 (at or above 1.5: strong)
Debt / equity Q 0.25 (at or below 0.5: strong)
Interest coverage Q 13.52
Growth
Revenue growth Q +10.96% (above 0%: growing)
Operating income growth Q +13.06% (above 0%: growing)
EPS, this year −25.00% (below 0%: weak)
EPS, next year A +8.74%
Revenue, next year A +6.64%
EPS, past 5 yrs +21.32% (at or above 15%: strong)
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.5×, against a ten-year median of 1.7×; over the ten years it ranged from 0.4× in 2016 to 3.9× in 2020.
P/E against its own 10 years 56.07%
10-year low 10-year high
P/S against its own 10 years 81.66%
10-year low 10-year high
P/B against its own 10 years 75.32%
10-year low 10-year high
EV/Sales against its own 10 years 82.76%
10-year low 10-year high
EV/FCF against its own 10 years 39.61%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 7 7 9 13
Receivables 14 17 22 19
Inventory 15 22 21 22
Other — — — —
37 47 53 54
2024 2025 2026 Q'26
Payables 5 5 4 5
ST’ Debt — — — —
Other — — — —
13 15 13 13

Compound Annual Growth %

10y 5y 3y
Sales 14.99% 15.32% 18.94%
Cash Flow 31.57% 0.00% 9.86%
Earnings 32.45% 17.23% 24.53%
Book Value 18.29% 18.85% 14.67%

Earnings Trends EPS, adjusted, against the consensus

Q1 FY27 Estimate 0.67 Actual 0.92

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.47 0.36 Miss by 0.11
Q1 FY26 0.50 0.62 Beat by 0.12
Q4 FY26 0.67 0.87 Beat by 0.20
Q1 FY27 0.67 0.92 Beat by 0.25
Q2 FY27 0.72 — Reports 4 February 2027

EPS $

Sep Dec Mar Jun Year
’26 0.92 — — — —
’26 1.40 0.66 1.20 0.87 4.12
’25 0.75 0.61 0.98 0.36 2.67
’24 (0.17) 0.14 0.19 0.46 0.60
’23 0.29 0.75 0.36 0.42 1.95
’22 0.28 0.25 0.12 0.56 1.21
’21 0.32 0.44 0.50 0.22 1.57
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 21 — — — —
’26 19 19 20 20 78
’25 15 17 17 17 67
’24 12 13 14 15 54
’23 11 11 13 11 46
’22 10 10 9 13 42
’21 9 8 12 9 38
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 6 — — — —
’26 2 4 2 0 7
’25 2 (4) 1 0 (2)
’24 0 1 4 1 6
’23 3 0 2 1 5
’22 3 2 0 (5) (1)
’21 (1) 2 (4) 1 (2)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 6 — — — —
’26 2 4 2 0 7
’25 1 (5) 1 0 (3)
’24 0 0 4 1 5
’23 3 (1) 2 0 4
’22 2 1 0 (6) (3)
’21 (1) (5) (4) 0 (10)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Sep ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 22 22 27 35 38 42 46 54 67 78 80 +15.1% 83 87 — +5.8%
Gross margin, % 32.75 35.36 35.99 37.73 35.70 31.24 27.66 27.02 29.30 31.38 32.45 (1.4) pt
EBT 3 3 5 8 8 6 9 3 12 18 15 +23.2%
EBT margin, % 12.54 11.62 20.05 22.68 20.03 13.54 20.46 4.89 18.11 23.23 19.07 +10.7 pt
Net income 5 2 4 6 6 5 7 2 9 14 12 +11.6%
Per share, $
Per share, $ Revenue 5.43 5.22 6.48 8.91 10.02 11.56 12.91 15.39 20.25 24.04 24.82 +18.0%
Earnings 1.26 0.38 0.99 1.56 1.63 1.26 1.98 0.61 2.73 4.24 3.75 +14.4%
Cash flow 0.80 0.72 0.79 1.26 (0.55) (0.23) 1.53 1.78 (0.51) 2.24 3.56 +12.1%
Capex (0.16) (0.21) (0.33) (0.14) (2.19) (0.46) (0.27) (0.28) (0.38) (0.15) (0.23) (0.5%)
Free cash flow 0.64 0.51 0.46 1.12 (2.73) (0.69) 1.26 1.50 (0.89) 2.10 3.33 +14.0%
Book value 3.39 4.01 4.06 4.87 5.29 6.99 8.85 8.82 11.14 14.77 15.39 +17.7%
Shares, m 4 4 4 4 4 4 4 3 3 3 3 (2.5%)
Valuation, ×
Valuation, × P/E 4.88 17.37 13.42 11.37 19.93 12.70 10.27 29.13 15.81 13.84 16.42 14.9
P/S 1.13 1.26 2.05 2.00 3.05 1.38 1.48 1.19 2.15 2.44 2.48 1.8
P/B 1.81 1.64 3.28 3.66 5.78 2.28 2.16 2.08 3.92 3.97 4.00 3.1
EV/Sales 0.91 0.94 1.85 1.84 3.22 1.59 1.59 1.21 2.19 2.49 2.47 1.8
EV/FCF 7.69 9.59 25.94 14.59 (11.80) (26.47) 16.40 12.46 (49.16) 28.67 18.45 2.8
Cash, $m
Cash, $m Operating cash flow 3 3 3 5 (2) (1) 5 6 (2) 7 11 +9.4%
Capex (1) (1) (1) (1) (8) (2) (1) (1) (1) 0 (1) (3.0%)
Free cash flow 3 2 2 4 (10) (3) 4 5 (3) 7 11 +11.2%
Balance, $m
Balance, $m Working capital 10 14 17 17 19 20 21 24 33 40 41 +17.1%
Net debt (5) (7) (6) (6) 7 9 5 1 2 4 (1) n/m
Shareholders’ equity 14 17 17 19 20 25 32 31 37 48 49 +14.8%
Returns, %
Returns, % ROA 36.98 8.94 18.26 21.58 17.27 10.23 14.02 4.08 15.80 20.14 17.08 (16.8) pt
ROIC 19.33 15.14 27.19 33.05 10.63 9.40 9.89 14.21 17.25 15.75 17.22 (3.6) pt
ROE 45.02 10.46 24.20 33.89 31.52 20.09 24.81 6.81 26.60 32.43 26.48 (12.6) pt
People
People Employees 76 80 97 117 118 135 146 148 181 206 — +11.7%
Revenue/emp, $m 0.29 0.28 0.28 0.30 0.32 0.31 0.32 0.36 0.37 0.38 — +3.0%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2026 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Pro-Dex, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ZJYL Jin Medical International Ltd. $509.4M — — — — −8,074.17% (below 0%: shrinking) 34.44% 0.00% Compare
ANGO AngioDynamics, Inc. $496.7M — (loss-making) — (loss-making) +6.87% (above 0%: growing) n/m +5.62% (above 0%: growing) 59.37% (9.02%) Compare
EMBC Embecta Corp. $358.7M 4.2× 5.3× −8.05% (below 0%: shrinking) −53.85% (below 0%: shrinking) −49.63% (below 0%: shrinking) 56.42% 17.92% Compare
SMTI Sanara MedTech Inc. $290.4M — (loss-making) 164× +9.04% (above 0%: growing) n/m +131.28% (above 0%: growing) 92.96% 6.33% Compare
OSUR OraSure Technologies, Inc. $232.4M — (loss-making) — (loss-making) −1.93% (below 0%: shrinking) n/m −1.40% (below 0%: shrinking) 43.46% 17.76% Compare
UTMD Utah Medical Products, Inc. $202.4M 21.7× 28.7× −14.31% (below 0%: shrinking) −10.64% (below 0%: shrinking) −55.74% (below 0%: shrinking) 55.79% 31.06% Compare
PDEX Pro-Dex, Inc. $195.8M 16.4× 18.8× +10.96% (above 0%: growing) −33.57% (below 0%: shrinking) +177.76% (above 0%: growing) 33.35% 17.10%
KRMD KORU Medical Systems, Inc. $139.9M — (loss-making) — (loss-making) +18.15% (above 0%: growing) n/m +26.17% (above 0%: growing) 65.14% 5.21% Compare
STXS Stereotaxis Inc. $105.2M — (loss-making) — (loss-making) −12.82% (below 0%: shrinking) n/m +0.45% (above 0%: growing) 58.49% (59.56%) Compare
Median of peers $261.4M — 28.7× −1.93% — −0.48% 57.46% 5.77%

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 6 October 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2026 727.58k 1.12m 306.54
2025 652.95k 1.95m 225.65
2024 441.30k 397.48k 102.83

Ownership

Directors and executive officers, together 48.00%
Minneapolis, MN 31.90%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Pro-Dex, Inc. (PDEX) Latest News

29 Oct

Impact 4 · · Zacks
Impact 3 · · ACCESS Newswire earnings

28 Oct

Impact 3 · · Zacks
Impact 3 · · Simply Wall St.

3 Sep

Impact 3 ·

10 Aug

Impact 4 ·

30 Apr

Impact 3 · · ACCESS Newswire

12 Feb

Impact 4 · · ACCESS Newswire

29 Jan

Impact 4 · · ACCESS Newswire

25 Jan

Impact 4 · · Simply Wall St.

19 Dec

Impact 4 · · ACCESS NewswireInsider MonkeySimply Wall St.Medical Device NetworkGuruFocus.comZacks

13 Dec

Impact 3 · · Simply Wall St.

1 Dec

Impact 3 · · Insider Monkey

22 Nov

Impact 4 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

1 Nov

Impact 3 · · Simply Wall St.

30 Oct

Impact 4 · · ZacksZacksZacksZacksZacksZacks
Impact 4 · · ACCESS Newswire

6 Sep

Impact 3 · · Simply Wall St.

4 Sep

Impact 4 ·
Impact 3 · · Zacks

18 Aug

Impact 3 · · Simply Wall St.

29 Jul

Impact 3 ·

23 Jun

Impact 4 ·

17 Jun

Impact 4 · · Zacks
Impact 4 · · Zacks

20 May

Impact 3 · · Simply Wall St.

4 May

Impact 4 ·
Impact 3 · · Simply Wall St.

1 May

Impact 4 ·
Impact 3 · · Zacks
stockrow.com/PDEX · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com